Phasic Insulin Release and Metabolic Regulation in Type 2 Diabetes
- 1 February 2002
- journal article
- review article
- Published by American Diabetes Association in Diabetes
- Vol. 51 (suppl_1) , S109-S116
- https://doi.org/10.2337/diabetes.51.2007.s109
Abstract
Type 2 diabetes is a heterogeneous disorder due to prevalent insulin resistance associated with deficient insulin secretion or to a prevalent defect of insulin secretion associated with impaired insulin action. The definition is supported by the high frequency at which insulin resistance can be demonstrated in type 2 diabetic patients. Nonetheless, insulin resistance is not a sufficient mechanism to cause diabetes. Impaired β-cell function is a necessary defect in all conditions of impaired glucose regulation; however, it manifests itself in a different manner in fasting and glucose-stimulated conditions. In the fasting state, the basal insulin secretory rate increases as a function of the progressive decline in insulin action. As such, the fasting plasma insulin concentration is often taken as a marker for insulin sensitivity. After glucose challenge, a specific alteration of acute insulin release is an early and progressive defect. The latter might represent an intrinsic defect, but its continuous decline is affected by glucotoxicity and lipotoxicity. To understand the impact of β-cell dysfunction in type 2 diabetes on metabolic homeostasis, it is useful to consider the different phases of insulin secretion separately. Insulin secretion can be divided into basal (postabsorptive) and stimulated (postprandial) states. The former prevails during the interprandial phases and plays a major role during the overnight fast; the latter regulates glucose metabolism when carbohydrate is abundant and must be disposed of. Data in animals and humans support a crucial physiological role of first-phase insulin secretion in postprandial glucose homeostasis. This effect is primarily achieved in the liver, allowing prompt inhibition of endogenous glucose production and limiting the postprandial rise in plasma glucose level. In type 2 diabetes, loss of the early surge of insulin release is an early and quite common defect that may have a pathogenetic role in the development of postprandial hyperglycemia, possibly requiring specific therapeutic intervention.Keywords
This publication has 47 references indexed in Scilit:
- The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitusJournal of Clinical Investigation, 1999
- Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis StudyDiabetes, 1997
- Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance.Journal of Clinical Investigation, 1996
- Loss of the First Phase Insulin Response to Intravenous Glucose in Subjects with Persistent Impaired Glucose ToleranceDiabetic Medicine, 1994
- Improvement of Basal Hepatic Glucose Production ana Fasting Hyperglycemia of Type I Diabetic Patients Treated With Human Recombinant Ultralente InsulinDiabetes Care, 1994
- Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus.Journal of Clinical Investigation, 1993
- β-Cell Dysfunction Induced by Chronic Hyperglycemia: Current Ideas on Mechanism of Impaired Glucose-Induced Insulin SecretionDiabetes Care, 1992
- Pathogenesis of NIDDM: A Balanced OverviewDiabetes Care, 1992
- Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1989
- Impaired Glucose Tolerance as a Disorder of Insulin ActionNew England Journal of Medicine, 1988